89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia - Marketscreener.com
| ETNB Stock | USD 9.81 0.58 6.28% |
About 55% of 89bio's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding 89bio Inc suggests that some traders are interested. The current market sentiment, together with 89bio's historical and current headlines, can help investors time the market. In addition, many technical investors use 89bio Inc stock news signals to limit their universe of possible portfolio assets.
89bio Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia Marketscreener.com
Read at news.google.com
 |
89bio Fundamental Analysis
We analyze 89bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 89bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 89bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
89bio is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
89bio Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 89bio stock to make a market-neutral strategy. Peer analysis of 89bio could also be used in its relative valuation, which is a method of valuing 89bio by comparing valuation metrics with similar companies.
Peers
89bio Related Equities
| XFOR | X4 Pharmaceuticals | 8.31 | ||||
| AKRO | Akero Therapeutics | 5.98 | ||||
| PLRX | Pliant Therapeutics | 5.47 | ||||
| ACLX | Arcellx | 4.14 | ||||
| STOK | Stoke Therapeutics | 3.18 | ||||
| ABOS | Acumen Pharmaceuticals | 2.94 | ||||
| HOOK | Hookipa Pharma | 1.90 | ||||
| TERN | Terns Pharmaceuticals | 1.66 | ||||
| TGTX | TG Therapeutics | 1.62 | ||||
| MREO | Mereo BioPharma | 0.91 | ||||
| DAWN | Day One | 0.16 | ||||
| VKTX | Viking Therapeutics | 0.18 | ||||
| INZY | Inozyme Pharma | 0.25 | ||||
| MDGL | Madrigal Pharmaceuticals | 0.35 |
Complementary Tools for 89bio Stock analysis
When running 89bio's price analysis, check to measure 89bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 89bio is operating at the current time. Most of 89bio's value examination focuses on studying past and present price action to predict the probability of 89bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 89bio's price. Additionally, you may evaluate how the addition of 89bio to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |